

1 **High proportion of genome-wide homology and increased basal *pvcrt* levels in**
2 ***Plasmodium vivax* late recurrences: a chloroquine therapeutic efficacy study**

3

4 Eduard Rovira-Vallbona^{1#}, Nguyen Van Hong², Johanna H. Kattenberg¹, Ro Mah Huan³,
5 Nguyen Thi Huong Binh², Nguyen Thi Hong Ngọc², Pieter Guetens¹, Nguyen Luong Hieu²,
6 Nguyen Thị Thu Hien², Vu Thi Sang², Nguyen Duc Long², Erin Sauve¹, Tran Thanh Duong²,
7 Nguyen Xuan Xa², Annette Erhart^{1,4}, Anna Rosanas-Urgell^{1#}

8

9 ¹ Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

10 ² National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam.

11 ³ Centre for Disease Control and Prevention, Gia Lai, Vietnam.

12 ⁴ Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical
13 Medicine, Fajara, The Gambia.

14

15 Running Head: Efficacy of CQ against *P.vivax* in Central Vietnam

16

17 #Address correspondence to Anna Rosanas-Urgell, arosanas@itg.be; Eduard Rovira-
18 Vallbona, edu.rovira@outlook.com

19

20 E.R.V. and N.V.H. contributed equally to this work.

21 **ABSTRACT**

22

23 Chloroquine (CQ) is the first-line treatment for *Plasmodium vivax* malaria in most endemic
24 countries. Monitoring *P.vivax* CQ resistance (CQR) is critical but remains challenged by the
25 difficulty to distinguish real treatment failure from reinfection or liver relapse. Therapeutic
26 efficacy of CQ against uncomplicated *P.vivax* malaria was evaluated in Gia Lai province,
27 Vietnam. Sixty-seven patients were enrolled and followed-up for 42 days using microscopy
28 and (RT)qPCR. Adequate clinical and parasitological response (ACPR) was 100% (66/66)
29 on Day 28, but 75.4% (49/65) on Day 42. Eighteen recurrences (27.7%) were detected with
30 a median time-to-recurrence of 42 days (IQR 35, 42) and blood CQ concentration <100ng/ml.
31 Parasite genotyping by microsatellites, SNP-barcoding and whole-genome sequencing
32 (WGS) identified a majority of homologous recurrences, with 80% (8/10) showing >98%
33 identity-by-descent to paired Day 0 samples. Primary infections leading to recurrence
34 occurred in younger individuals (median age for ACPR=25 years [IQR 20, 28];
35 recurrences=18 [16, 21]; p=0.002), had a longer parasite clearance time (PCT for
36 ACPR=47.5h [IQR 36.2, 59.8]; recurrences=54.2h [48.4, 62.0]; p=0.035) and higher *pvcrt*
37 gene expression (median relative expression ratio for ACPR=0.09 [IQR 0.05, 0.22];
38 recurrences=0.20 [0.15, 0.56]; p=0.002), but there was no difference in *ex vivo* CQ
39 sensitivity. This study shows that CQ remained largely efficacious to treat *P.vivax* in Gia Lai,
40 *i.e.* recurrences occurred late (>Day 28) and in the presence of low blood CQ concentrations.
41 However, the combination of WGS and gene expression analysis (*pvcrt*) with clinical data
42 (PCT) allowed to identify potential emergence of low-grade CQR that should be closely
43 monitored.

44

45 INTRODUCTION

46

47 *Plasmodium vivax* was responsible for 6.4 million malaria cases globally according to the
48 World Health Organization (WHO) estimates for 2019, with most of them occurring in Asia
49 (1). Historically mistaken as benign, *P. vivax* is becoming the predominant malaria species
50 in countries where the incidence of *Plasmodium falciparum* is decreasing as they are moving
51 towards malaria elimination (2). Whereas addressing asymptomatic infections and drug
52 resistance are cross-cutting issues in the elimination of both *P. vivax* and *P. falciparum*, the
53 treatment and control of *P. vivax* present additional unique challenges due to key biological
54 differences, such as the presence of liver hypnozoites responsible for relapses (*i.e.*
55 reactivation of dormant parasite forms leading to blood-stage infection), the low parasite
56 density in peripheral blood, and the production of gametocytes (*i.e.* parasite transmissible
57 stages) before the onset of symptoms (2,3).

58

59 Chloroquine (CQ) is the first-line drug treatment for *P. vivax* in most endemic countries (1).
60 Chloroquine resistance (CQR) in malaria parasites emerged first in *P. falciparum* shortly after
61 the start of widespread use as an antimalarial treatment in the 1950s (4). The first report of
62 *P. vivax* CQR emerged 30 years later in Papua New Guinea and, since then, decreasing
63 efficacy of CQ against *P. vivax* has been reported across malaria endemic areas around the
64 world, although with different degrees of certainty (3,4). In countries where high level CQR
65 has been confirmed (*i.e.* Papua New Guinea, Indonesia and Malaysia) artemisinin-based
66 combination therapies have been adopted as the universal antimalarial first-line treatment
67 instead of CQ (1,4).

68 In order to evaluate the efficacy of CQ regimens against *P. vivax*, the WHO recommends to
69 conduct therapeutic efficacy studies (TES) with at least 28 days of patient follow-up after
70 treatment administration (5). Recurrences within this period with a confirmed CQ blood
71 concentration over the minimum effective concentration (MEC) of 100 ng/ml would support
72 the presence of CQR. However, it has also been shown that a long-acting antimalarial drug
73 like CQ can linger in the bloodstream for approximately 35 days and delay appearance of
74 relapses up to six weeks (6,7). Extended follow-up periods of 42 or 63 days are therefore
75 recommended to detect recurrences with parasites at early stage of CQR (5,8). Nonetheless,
76 a main challenge of *P. vivax* TES studies is to distinguish a parasite recrudescence caused by
77 real treatment failure from a relapse or new infection, for which additional *ex vivo* and *in*
78 *vitro* laboratory tests are required (8). On one hand, genotyping of parasites at polymorphic
79 genome regions can show whether recurrent parasite clones differ from those in the initial
80 infection -especially when using high-resolution approaches at whole-genome level (9,10)-
81 but if applied alone they remain limited to unambiguously differentiate a recrudescence from
82 a genetically homologous relapse. On the other hand, short-term *ex vivo* cultures of isolates
83 exposed to CQ and genotyping of drug resistance markers can be combined to characterize
84 isolates CQR properties.

85 The identification and validation of CQR markers in *P. vivax* has unfortunately been
86 hampered by the inability to long-term culture the parasite and evaluate adaptation to
87 extended drug-exposure (11). Despite this limitation, numerous studies have linked CQR to
88 both chloroquine resistance transporter (*pvcrt*) and multidrug resistance gene-1 (*pvmdr1*)
89 genes. Associations with SNPs and/or copy number variation in both *pvcrt* and *pvmdr1* have
90 remained weak and sometimes contradictory (12–16). At the transcriptional level, increased
91 expression of *pvcrt* and *pvmdr1* was found in CQR infections from the Brazilian Amazon

92 (17), whereas *pvcrt* expression was upregulated in a genetic cross of *P. vivax* parasites
93 differing in their CQ response in experimental non-human primate infections (18).

94

95 In Vietnam, *P. vivax* accounts for 40% of all malaria cases, which occur mainly among ethnic
96 minorities in forested areas in central and southern provinces (19). National guidelines for
97 the treatment of *P. vivax* infection follows WHO recommendation of 3 days of CQ (25
98 mg/kg) followed by 14 days of primaquine (PQ; 0.25 mg/kg) radical-cure treatment to
99 eliminate liver hypnozoites. To date, only one study conducted in Quang Nam province
100 (Central Highlands) between 2009-2011 confirmed *P. vivax* CQR by reporting a 3.5% failure
101 rate (n=8) at Day 28 and three cases with CQ blood concentrations >100ng/ml, although no
102 genetic analysis of recurrences were performed (20). A few other reports of suspected *P.*
103 *vivax* CQR have been published in the last twenty years in Binh Thuan, Binh Phuoc and Ninh
104 Thuan provinces (recurrence rates at Day 28 or later ranging 13%-57%), but CQR could not
105 be confirmed due to the lack of either blood CQ levels or genotyping of recurrent infections
106 (21)(22)(23).

107

108 In the present study we assessed the *in vivo* susceptibility of *P. vivax* to CQ in Gia Lai
109 (Central Vietnam), the province with the highest malaria burden in the country in recent years
110 (19,24). We used good manufacturing practice certified CQ and administered the currently
111 recommended radical cure regimen of PQ at the end of the 42 days of follow-up. Importantly,
112 we provide a thorough analysis of treatment failures by combining *ex vivo* drug sensitivity
113 assays, three technical approaches to genetic analysis of recurrences, as well as genotyping
114 of candidate markers of drug-resistance including gene expression analysis.

115

116 MATERIALS AND METHODS

117

118 Study site

119 The study was conducted between May 2015 and February 2017 in Chu R'Cam commune's
120 health center (CHC), Krong Pa district (Gia Lai province, Central Highlands, Vietnam),
121 where a small field laboratory was set-up. In addition, CHC in the nearby communes of Ia
122 R'Sai, Ia R'Suom and Uar were asked to refer all potentially eligible patients to the reference
123 CHC. Chu R'Cam is located 120 km south-east of the provincial capital Pleiku, next to the
124 Ba river in a large valley surrounded by hilly and partially forested areas (25). The local
125 population is mainly from J'Rai ethnic minority, which has in general a low socio-economic
126 status and education level. Local housing structures consist of government supported brick
127 or wooden houses built on concrete floors. The main occupation is slash-and burn agriculture
128 in forest fields, which often requires sleeping in the forest. The climate is tropical, with the
129 dry season from November to April and the rainy season from May to October. Malaria
130 transmission usually begins in May and peaks from September to December, with the lowest
131 incidence between February and April. At the time of study initiation in 2015, Gia Lai
132 province had reported 4367 microscopically confirmed malaria cases, the highest burden in
133 the country, of which 1051 *P. falciparum* and 1124 *P. vivax* occurred in Krong Pa district
134 (19,24). Malaria control by the provincial malaria station relies on early diagnosis by light
135 microscopy (LM) or rapid diagnostic tests, annual distribution of long-lasting insecticidal
136 treated nets, promotion of community-based prevention behavior and monitoring of drug
137 resistance through regular TES. The presence of *P. falciparum* artemisinin resistance was
138 confirmed in the province in 2017 (25).

139

140 **Study design and trial procedures**

141 The study was designed as a 42-day drug efficacy study to evaluate clinical and
142 parasitological responses after treatment of *P. vivax* uncomplicated malaria infections.
143 Patients aged >1 year-old presenting to the CHC with fever ($\geq 37.5^\circ\text{C}$) and/or history of
144 fever during the previous 48 hours were screened for malaria infection by blood smears from
145 finger prick, and hemoglobin (Hb) concentration was measured using Hb201+ System
146 (Hemocue). Those with LM confirmed *P. vivax* mono-infection and asexual parasite density
147 >250 parasites/ μl were invited to enroll and provide written informed consent. Individuals
148 diagnosed with *P. falciparum* or mixed infections, signs of severe malaria, febrile diseases
149 other than malaria, or any chronic medical condition, as well as pregnant and breastfeeding
150 women, were excluded. Prior to treatment, 5 ml of whole blood was collected by
151 venepuncture for nucleic acid purification and *ex vivo* drug assays (200 μl were transferred
152 into an EDTA microtainer, 100 μl were transferred into an RNAprotect-containing
153 containing tube and stored at -20°C , and remaining blood was processed as described below).
154 After treatment initiation patients remained in the health center where they were monitored
155 by LM every 12 hours for 72 hours (Day 3) or until parasite clearance was confirmed by two
156 consecutive LM negative slides. On Days 7, 14, 28, 35 and 42 patients were asked to return
157 for follow-up visits or were visited at home by health centre staff. At each visit, a finger prick
158 was conducted to prepare thick and thin smears, 200 μl of blood was transferred into an EDTA
159 microtainer (for DNA extraction), and another 100 μl was transferred into an RNAprotect-
160 containing tube (for RNA extraction). On Day 7, 100 μl of blood were collected onto
161 chromatography paper for drug concentration measurements (31ETCHR, Whatman). Hb
162 levels were measured on Days 14, 28, and 42. In case of confirmed recurrence, a 5ml venous
163 blood sample and a blood spot on chromatography paper were collected prior to rescue

164 treatment administration. A system of passive detection of fever cases was maintained
165 throughout the study period.

166

167 **Treatment**

168 All patients received a full treatment with CQ (Nivaquine®, Sanofi) at a total dose of 25mg
169 of CQ base/kg body weight, given over 3 days and under direct observation (10mg the first
170 two days and 5mg on the third)(26). Exact dosage given per patient was registered on case
171 report forms. Individuals who vomited their medication within the first 30 minutes after
172 treatment received another full dose, whereas those vomiting between 30 and 60 minutes
173 after treatment received another half dose. The time when patients received the first dose was
174 defined as Day 0. PQ (0.25mg/kg/day for 14 days, Sanofi/Valeant Pharmaceuticals) was
175 given at the end of follow-up on Day 42 to all patients testing negative for glucose-6-
176 phosphate dehydrogenase deficiency (G6PD; CareStart, Access Bio) under supervision of
177 health workers. Patients with recurrences at Day 42 or earlier were administered radical cure
178 treatment as per national guidelines, consisting of CQ (25mg/kg, 3 days) together with PQ
179 (0.25mg/kg/day for 14 days)(26).

180

181 **Microscopy**

182 Malaria diagnosis by LM was conducted by examining thick and thin smears stained with
183 freshly prepared 10% Giemsa for 15 min under 1000X magnification. Parasite density was
184 calculated by counting the number of asexual parasites per 200 white blood cells (WBC) with
185 a hand tally counter and expressed as parasites/ μ l of blood assuming a WBC density of 8000
186 cells per μ l. Blood smears were considered negative when no asexual parasites were found
187 after counting 1000 WBC. All smears were read in duplicate by two trained microscopists

188 and the final density was expressed as the average result. A third reading was conducted by
189 another technician in case of discrepancy in positivity, species diagnosis, or parasite count
190 by >25%. Fifteen per cent randomly selected blood smears were sent to ITM (Antwerp,
191 Belgium) for external quality control.

192

193 ***P. vivax* quantification by (RT)qPCR**

194 DNA was extracted from 200 µl whole blood in EDTA using Favorprep 96-well Genomic
195 DNA kit (Favorgen) and eluted in 200 µl of water. Duplex qPCR targeting *P. vivax* and *P.*
196 *falciparum* 18S ribosomal RNA genes was performed in samples from Day 0 using TaqMan
197 Universal Master Mix II and StepOne Plus Real-Time PCR System (Applied Biosystems)
198 (27). The same method was adapted as a *P. vivax* monoplex qPCR and used for *P. vivax*
199 quantification in follow-up samples. RNA was extracted from RNAprotect samples collected
200 at Day 0 and from all follow-up samples positive in the *pv18S rRNA* qPCR, using RNeasy
201 Plus 96- kit (Qiagen) (25). Final RNA elution was conducted in 100 µl of RNase-free water,
202 and the presence of quality RNA was confirmed in a random selection of 80 samples by one-
203 step reverse transcription qPCR (RTqPCR) targeting *pv18S rRNA* transcripts, using
204 LightCycler Multiplex RNA Virus Master mix in a LightCycler480 thermocycler (Roche).
205 The presence of *P. vivax* stage V gametocytes was determined by RTqPCR amplification of
206 *pvs25* RNAs (28). A standard curve (10^6 -1 copies/µl) of plasmids containing the *pvs25* PCR
207 fragment was included in each plate for copy number quantification (28).

208

209 ***Ex vivo* schizont maturation assays (SMA)**

210 Venous blood vacutainers were centrifuged, and plasma and buffy coat stored at -20°C.
211 Infected red blood cells (iRBC) were diluted to 25% haematocrit in sterile PBS and passed

212 through an autoclaved 10ml syringe (Terumo, SS10LE1) prefilled with cellulose powder
213 2.5ml-layer (Sigma-Aldrich, C6288) on top of a lens-cleaning paper to remove white blood
214 cells. In all samples with a ring-stage proportion $\geq 65\%$, 150 μl iRBC were separated for *ex*
215 *vivo* drug sensitivity SMA and remaining iRBC pellet was cryopreserved in liquid nitrogen
216 or stored at -20°C . SMA was performed by adapting WHO microtest, as previously described
217 (25,29). A stock solution of 640 μM CQ in water (Sigma-Aldrich, C6628) was pre-dosed in
218 seven 2-fold serial dilutions in water (800-12.5nM), and 25 μl /well were distributed in a 96-
219 well plate, air-dried overnight inside a laminar-flow cabinet and stored at 4°C (30). The 150 μl
220 iRBC were resuspended to 2% hematocrit in pre-warmed McCoy's 5A medium (Gibco)
221 supplemented with 20% human serum (non-exposed Vietnamese individuals), and 200
222 μl /well of the iRBC-medium mixture were added to pre-dosed plates, including drug-free
223 wells. Plates were cultured at 37°C and drug-free wells monitored by LM at 34h, and
224 thereafter every 2-4h until the number of schizonts reached 40% (or until 42 hours). The
225 percentage of schizonts per each drug concentration was determined by double-reading of
226 blood smears and result expressed as schizonts % relative to the drug-free well. Half maximal
227 inhibitory concentrations (IC50) were calculated using WWARN's online In Vitro Analysis
228 and Reporting Tool (31).

229

230 **Drug concentration in blood**

231 Concentrations of CQ and desethyl-chloroquine (DCQ, *i.e.* the main chloroquine metabolite)
232 were measured in paired samples on Day 7 and Day of recurrence (DRec). Blood expelled
233 onto chromatography papers was air dried and stored in separate plastic bags with silica gel.
234 Drug measurements were conducted by liquid chromatography–mass spectrometry at the
235 Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine Research Unit

236 (Bangkok, Thailand). The minimum effective concentration (MEC) was considered a
237 [CQ]+[DCQ] value of 100 ng/ml (8).

238

239 **Microsatellites genotyping**

240 Paired Day 0 and DRec samples were genotyped at polymorphic markers Pvmsp1F3, MS4,
241 MS10 and PvSal1814, selected based on the high degree of heterozygosity found in Central
242 Vietnam and adapting previously published protocols (see Table S1) (32) (33,34). All
243 products were run on a 2% agarose gel, and 20µl pool of Pvmsp1F3 (5µl), MS4 (7.5µl) and
244 MS10 (7.5 µl) PCR products and PvSal1814 products were sent off for capillary
245 electrophoresis at Genoscreen (Lille, France). Allele calling was performed using GeneTools
246 (Syngene) and GeneMarker v2.4.0 (Softgenetics). All samples were double-checked
247 manually and the predominant allele (*i.e.* the highest peak) and minor alleles within at least
248 two-thirds of the height of the predominant allele were scored. Alleles were considered
249 identical if size difference was ≤ 2 bp. Complexity of infection (COI; *i.e.* the estimated
250 number of genetically distinct clones within an infection) was defined as the highest number
251 of alleles found in any of the four markers. Genotypes at Day 0 and DRec were classified as
252 homologous (when all or some of the alleles present in Day 0 sample were found in DRec
253 sample for all markers), heterologous (when none of the alleles present in Day 0 sample were
254 found at DRec for at least one marker), or indeterminate (when no amplification was achieved
255 for any marker).

256

257 **SNP barcode**

258 A molecular barcode consisting of 38 SNPs across the *P. vivax* genome was used to genotype
259 samples in the context of MalariaGEN SpotMalaria Project (Wellcome Sanger Institute,

260 Hinxton, UK), using MALDI-TOF mass spectrometry of PCR amplicons in a
261 MassARRAY® System (Agena BioScience) (25)(35). Nucleotide sequence results were
262 provided in the form of a Genetic Report Card (see Data S1). Recurrences were classified as
263 homologous to Day 0 if there were no nucleotide differences in any non-heterozygous
264 position of the barcode, irrespective of the total number of successfully genotyped SNPs.

265

266 **Whole-genome sequencing**

267 DNA was initially subject to selective whole-genome amplification (sWGA) with *phi29*
268 DNA polymerase (New England Biolabs) according to previously published methodology
269 (30 µl of DNA in 50 µl reaction volume)(36). Product was purified with AMPure XP beads
270 (Beckman-Coulter) and 15µl were used in a second sWGA round (50 µl reaction volume).
271 Final sWGA purified product concentration was determined in a Qubit 2.0 Fluorometer (Life
272 Technologies), and a minimum of 1mg was sent to BGI (Hong Kong) for library preparation
273 and 150bp paired-end WGS on a HiSeq X Ten (Illumina). FASTQ files were trimmed using
274 Trimmomatic to remove adapters and low quality reads, and aligned to the reference genome
275 *PvP01* using the BWA-MEM algorithm v0.7.17 (37). Variants were called using
276 HaplotypeCaller in GVCF mode followed by Joint-Call Cohort (GATK 4.1.2.0, Broad
277 Institute) and filtered to include only biallelic SNPs in the core genome, MQ>50, QUAL>30
278 and combined DP ≥100, resulting in 191849 high quality SNPs (38). Samples with at least
279 10X coverage were kept for subsequent analysis (see Table S2). Within-host infection
280 complexity was assessed using within-sample F statistic (FWS) and FWS>0.95 was
281 considered as a proxy for a monoclonal infection (39,40). Pairwise comparisons between all
282 samples were analysed in as identity-by-state (IBS) and identity-by-descent (IBD). For the
283 IBS approach, the proportion of discordant SNPs was determined by calculating the Prevosti

284 distance (*i.e.* number of allelic differences/number of possible differences). Distance was
285 fitted as the sum of four Gaussian distributions and the mean of the lowest distribution was
286 set as the threshold for IBS-homologous recurrence (see Fig S1). For the IBD analysis, PED
287 and MAP file formats were created from using VCFtools and the proportion of the genome
288 IBD between pairs of samples was calculated using isoRelate R package (41). Genetic
289 distance was calculated using estimated mean map unit size from *P. chabaudi chabaudi* of
290 13.7 kb/cM (42). We set thresholds of IBD on the minimum number of SNPs (20) and length
291 of IBD segments (50,000) reported to reduce false positive calls. Pairwise comparisons with
292 $\geq 95\%$ of their genome identical-by-descent were considered homologous and all pairwise
293 comparisons with shared IBD $< 95\%$ were considered heterologous.

294

295 **Molecular markers of drug resistance**

296 Gene expression of *pvcrt* and *pvm-dr1* were determined directly on RNA samples by one-step
297 RTqPCR. *β -tubulin* was used as reference gene. Each 10 μ l reaction volume contained 2 μ l of
298 LightCycler EvoScript RNA SYBR Green I Master (Roche), 0.4 μ M of forward and reverse
299 primers (from ref. (17)), and 2.5 μ l of RNA template. LightCycler480 (Roche) thermal
300 cycling conditions were 60°C for 15 minutes, 95°C for 10 minutes, 45 cycles of 95°C for 10
301 seconds and 58°C for 30 seconds, followed by a melting curve step to ensure amplification
302 specificity. Samples were run in triplicate and excluded from calculations if final SD of
303 duplicates after removal of outliers was > 0.4 . Gene expression was estimated using the
304 efficiency-adapted Pfaffl relative quantification model (43), in which the relative expression
305 ratio (R) is calculated as the efficiency of the target genes (see Fig S2) raised to the power of
306 the Ct difference between a given sample and a control (*i.e.* mean Ct + 2*SD of all Day 0
307 samples with ACPR), and divided by the same formula applied to reference gene *β -tubulin*.

308 Mutations in *pvmdr1* codons 976 (Y→F) and 1076 (F→L) were genotyped by nested PCR
309 amplification using primers from *Golassa et al* (primary) and *Lin et al* (nested; see Table S1)
310 (44,45). The 646bp amplification products were sequenced at Genoscreen (Lille, France).
311 Nucleotide sequences (Genbank accession numbers MW245736-MW245808) were entered
312 to BioEdit 7.0 and aligned using ClustalW with default parameters.

313

314 **Clinical trial endpoints**

315 The primary endpoint was adequate clinical and parasitological response (ACPR) at 28 and
316 42 days of follow-up. Treatment failures were classified as early treatment failure , late
317 clinical failure (LCF, *i.e.* parasitemia with fever or signs of severe malaria between Day 4
318 and Day 42) or late parasitological failure (LPF, *i.e.* parasitemia between Day 7 and Day 42),
319 based on WHO guidelines (5). Patients who discontinued due to reappearance of parasites
320 and subsequent rescue treatment were considered evaluable for Day 42 endpoint analysis.
321 Secondary endpoints were parasite clearance estimates obtained from the log_e parasitemia-
322 time LM data entered into WWARN Parasite Clearance Estimator (46), asexual and sexual
323 parasite carriage on Day 0-3 and during follow-up (including submicroscopic) and severe
324 anemia (Hb<7g/dl) on Day 7.

325

326 **Statistical analysis**

327 For sample size calculation, the initial estimation of 5% treatment failure rate (based on the
328 Quang Nam study (20)) was amended to 20% upon completion of the first year of the study,
329 after observing treatment outcome results together and an extremely low malaria incidence
330 in the district. To detect a minimum failure rate of 20%, a minimum sample size of 61 patients
331 was necessary (10% precision and 95% confidence level), which was extended to 67 to allow

332 for 10% loss to follow-up. All clinical data were double entered into a Microsoft Access
333 database and transferred to Stata v11.0. The primary study outcomes were analysed using
334 both *per-protocol* and intention-to-treat (ITT) patient population. Comparisons between
335 groups for continuous variables were performed using Wilcoxon rank-sum test and
336 proportions were compared using Chi-square or Fisher's exact tests, when appropriate.
337 Correlation between variables was assessed by Spearman's test. Clearance time for total
338 parasites and for gametocytes was estimated using Kaplan–Meier survival curves and
339 comparisons between subgroups were done using log-rank test. Time was computed in hours
340 and since treatment administration. Gene expression data was log-transformed, and
341 comparisons between groups were performed by pairwise Wilcoxon rank-sum test, with
342 Benjamini & Hochberg correction in cases of multiple testing. A linear model adjusted for
343 the proportion of ring-stage parasites was applied to investigate the potential effect of stage
344 composition on gene expression (47). Paired analyses between Day 0 and DRec were done
345 using Wilcoxon matched-pairs signed-rank test. Statistical analysis and graphs were
346 performed in Stata v11.0, R v4.0 or GraphPad Prism (v9.0). *P*-values <0.05 were considered
347 statistically significant.

348

349 **Ethics approval and consent to participate**

350 The study received approval from ethics committee of the NIMPE-Ministry of Health, Hanoi,
351 Vietnam (351/QD-VSR and QD2211/QD-BYT); the Institutional Review Board of the
352 Institute of Tropical Medicine, Antwerp, Belgium (937/14); and the ethics committee of
353 Antwerp University Hospital (UZA), Antwerp, Belgium (14/15/183). Written informed
354 consent was obtained from all participants or their respective parents/guardians in case of
355 minors. The trial was registered on ClinicalTrials.gov under identifier NCT02610686.

356 **RESULTS**

357

358 **Patient recruitment and characteristics at baseline**

359 A total of 480 patients were screened at the different CHC out of which 68 (14.2%) had *P.*
360 *vivax* infection confirmed by LM. Sixty-seven were enrolled and completed CQ treatment
361 (Fig 1). Twenty-seven (40.3%) patients self-presented at Chu R'Cam CHC, whereas the other
362 40 (59.7%) were referred from nearby communes. The age range was 8 to 45 years old and
363 most patients were male (91%; Table 1). Two thirds of participants reported having had an
364 episode of malaria in the past year (62.7%).

365

366 Fever was detected in 56 patients (83.6%) at the time of enrolment, 7 patients (10.4%)
367 presented anemia (Hb<11g/dL) and 1 patient was detected with G6PD deficiency. All
368 patients reported headache and fatigue together with other clinical symptoms, most
369 commonly dizziness and chills. Up to 87% of infections carried detectable level of
370 gametocytes by LM (Table 1). Asexual parasite density was significantly correlated with
371 body temperature ($\rho=0.435$, $p<0.001$), density of gametocytes ($n=58$; $\rho=0.525$, $p<0.001$) and
372 proportion of ring stages ($n=64$; $\rho=0.431$, $p<0.001$) but did not differ between age groups
373 ($p=0.971$).

374

375 **CQ efficacy endpoints**

376 Overall, CQ treatment was well tolerated, with 3 patients reporting moderate adverse effects
377 (dizziness, diarrhea, and abdominal pain). The median CQ dose received by patients was 24.5
378 mg/kg (IQR 24.0-25.4). Endpoint analysis was conducted using LM data. PCT and parasite
379 clearance half-life ($PC_{1/2}$) were estimated at 48.3 h (maximum 95.3 h) and 4.1 h (max.13 h),

380 respectively (Table 2). All patients were negative by LM at Day 4. Sixty-six (98.5%) and 65
381 (97.0%) patients completed the 28-day and the 42-day follow-up, respectively (Table 2). At
382 Day 28, the rate of ACPR was 100% (98.5% [66/67] based on ITT analysis), whereas at Day
383 42 the rate of ACPR was 75.4% (73.1% [49/67] based on ITT analysis). Out of 16
384 recurrences, three presented with fever (LCF, days 33-42), while the other 13 were afebrile
385 (LPF, >Day 35). Mean parasitemia at recurrence was 538.7 parasites/ μ l (95% CI 227.8,
386 1274.0), and was higher in LCF (n=3; 3024.2 parasites/ μ l [95% CI 1946.9, 4697.6])
387 compared to LPF (n=13; 361.7 [95% CI 143.5, 911.9]; p=0.026). Gametocytes were observed
388 in 6/16 (37.5%) infections at DRec.

389

390 After qPCR correction, parasite clearance rate did not differ significantly from that
391 determined by LM (p=0.338, log-rank; Fig 2A), although the number of Day 3 positives
392 increased to 13.9% (9/65) by qPCR as compared to 3% (2/65) by LM. On the other hand,
393 gametocyte clearance rate was significantly slower by RTqPCR than by LM (p<0.001, log-
394 rank; Fig 2B), and 11.3% were found gametocyte-positive on Day 3. Two additional
395 recurrences were detected by molecular methods on Day 42 (total recurrences=18), resulting
396 in a qPCR-corrected ACPR of 73% at the end of the 42-day follow-up (68.7% [46/67] as per
397 ITT analysis).

398

399 All 18 recurrences occurred after day 33 (median 42 days [IQR 35-42]; mean 38.7; range 33-
400 43 days) and affected younger individuals (median age 18 years old [IQR 16, 21]), as
401 compared to patients with ACPR (25 years [IQR 20, 28], p=0.002; Table 4). Recurrent and
402 non-recurrent infections did not differ in the CQ dose administered (24.6 mg/kg [24.0, 25.5]
403 *versus* 24.5 mg/kg [IQR 24.0, 25.0]; p=0.787). Blood concentrations of CQ and DCQ at

404 DRec were found to be below 100ng/ml (median 30.3 ng/ml [IQR 15.2, 36.4]; max. value
405 52.3ng/ml) in the 14 patients with valid test result (all Day 7 concentrations were >100ng/ml:
406 502 ng/ml [IQR 358, 601]; n=15). PCT was longer in infections that presented recurrence
407 (n=18; 54.2h [IQR 48.4, 62.0]) compared to those with ACPR (n=46; 47.5h [IQR 36.2, 59.8],
408 p=0.035; Table 4), and a similar trend was observed for PC_{1/2} (recurrent: 4.8h [IQR 4.0, 5.5];
409 ACPR: 4.0h [IQR 3.4, 5.2], p=0.078). Asexual parasitemia at Day 0 was not significantly
410 different between recurrent (n=49; mean 6762.3 p/ul [95% CI 3811.7, 11997.0]) and non-
411 recurrent infections (n=16; 7114.3 p/ul [95% CI 3726.7, 13581.3], p=0.462), and neither was
412 positivity at Day 2 (p=0.409) or Day 3 (p=0.772; Table 4).

413

414 **Genotyping of recurrent infections**

415 Treatment failures were corrected by genotyping approaches and classified as genetically
416 homologous or genetically heterologous infections relative to the initial infection at Day 0,
417 using three technical approaches in increasing order of resolution. Initially, Day 0/DRec
418 sample pairs were genotyped at four MS markers by PCR and capillary electrophoresis
419 (Table 3 and Table S3). Overall, 2/18 (11%) samples at Day 0 and 4/15 (27%) at DRec were
420 monoclonal. Fifteen sample pairs had data for at least 2 markers (Table 3). Median COI was
421 3 (IQR 2-3) at Day 0 compared to 2 (IQR 1-3) at DRec (p=0.080, signed-rank). Homologous
422 recurrences by MS accounted for 80% (12/15) of total recurrences.

423 In a second step, recurrences were genotyped using a 38-SNP molecular barcode (35).
424 Barcodes were successful in 11 Day 0/DRec sample pairs, although two of them at only 20
425 and 22 SNP positions, respectively (Table 3 and Data S1). COI was 1 (IQR 1-1) at Day 0 and
426 2 (IQR 1-2) at DRec (p=0.034, signed-rank). Homologous recurrence rate was 55% (6/11).

427 Compared to MS (n=10 pairs), the SNP-barcode identified 4 additional heterologous
428 infections and categorized two MS-heterologous infections as homologous.
429 Finally, samples were subject to WGS aiming for a maximum level of resolution. Fourteen
430 Day 0/DRec DNA sample pairs generated sequencing reads in both samples. Mean
431 sequencing coverage ranged from 1.6–50.1 (overall mean 30.3 ± 14.5) and there was no
432 significant difference in coverage between samples from Day 0 and DRec ($p=0.280$, paired
433 t-test; Table S2). COI was 1 in 58% (7/12) of samples at Day 0 and 73% (8/11) at DRec.
434 WGS analysis of identity-by-state (IBS; *i.e.* number of discordant SNP) identified 60% (6/10)
435 of homologous recurrences (Table 3). Compared to MS (n=9 pairs), IBS categorized three
436 originally homologous recurrences as heterologous. WGS data analysis of identity-by-
437 descent (IBD; *i.e.* considering inheritance from a common ancestor) identified 80% (8/10)
438 recurrent infections as homologous, all of them with >98% of their genome identical-by-
439 descent with the paired Day 0 sample (median 99.7% [IQR 0.3%], n=8). Median IBD found
440 between Day 0/DRec pairs (99.6% [IQR 98.4–99.8%], n=10) was significantly higher than
441 the IBD found in all between-patient comparisons (0% [IQR 0–0.60%], n=196, $p<0.001$,
442 Mann-Whitney U Test), suggesting it is unlikely that high IBD observed is caused by
443 independent infections with a closely related clone. Results between IBS and IBD were
444 discordant in 2 out of the 10 sample pairs (patients 022 and 043), which had a considerably
445 high number of discordant SNP by IBS (6.8% and 12.6%) but high IBD proportion (98.1%
446 and 99.8%); mean sequencing coverage was >34.2 for both samples and timepoints.
447 Assuming IBD provides the highest level of resolution and most restricted definition of
448 homology, the final rate of homologous recurrence (IBD-homologous) in the study was of at
449 least 12% (8/65) out of all patients that completed the 42-day of follow-up, and of at least
450 44% (8/18) out of total recurrences.

451

452 Compared to patients with ACPR, patients with IBD-homologous recurrences (n=8) were
453 not different in CQ uptake (24.1 mg/kg [IQR 23.0, 25.2], p=0.565) or parasite density at Day
454 0 (p=0.142; Table 4). However, median PCT among IBD-homologous was significantly
455 longer than in those with ACPR (p=0.019).

456

457 **Drug-resistance characteristics**

458 Phenotypic assessment of CQ susceptibility was conducted using the short-term schizont
459 maturation assays at Day 0. A total of 41 cultures were conducted out of which 21 were valid
460 for analysis (51% success rate). The overall CQ IC₅₀ geometric mean was 40.4 nM (95% CI
461 31.5, 51.8; range 10.4-108.0). There were no differences in *ex vivo* CQ sensitivity between
462 recurrent and non-recurrent infections (Table 4 and Fig 3).

463

464 At genetic level, mutations in *pvmdr1* codons F976Y and F1076L were common (30.2%
465 [19/63] for F976Y and 95.2% [60/63] for F1076L) but no differences were found in
466 prevalence of mutations between treatment outcome groups at Day 0 (Table 4). In samples
467 sequenced at DRec (n=10), F976Y and F1076L variants were found in 20% (2/10) and 100%
468 (10/10) of the sequences, respectively.

469

470 Gene expression of *pvcrt* and *pvmdr1* was determined in all samples with sufficient RNA
471 quantity at both Day 0 (n=51) and DRec (n=13). At Day 0, median *pvcrt* levels were 2.2-fold
472 higher in infections that led to recurrence as compared to those with ACPR (p=0.002,
473 Wilcoxon rank-sum), an increase that was also observed when only IBD-homologous
474 recurrences were considered (Table 4). No difference between treatment outcome groups at

475 Day 0 was found for *pvmdr1* levels ($p=0.138$; Table 4). Comparisons at Day 0 were not
476 affected after adjustment by multiple comparisons (Fig 4). We did not find an association
477 between ring-stage proportion and gene expression of either *pvcrt* in linear regression models
478 to suggest there was a potential confounding effect of parasite life-stage on transcript levels
479 (see Fig S3). There was no correlation between parasite *ex vivo* CQ susceptibility (defined
480 by IC50 values) and gene expression of *pvcrt* ($n=13$; Spearman's $\rho=-0.217$, $p=0.476$) or
481 *pvmdr1* ($n=17$; Spearman's $\rho=-0.120$, $p=0.646$).

482 Parasites collected at DRec showed a wide range of *pvcrt* expression levels ($n=9$; $R=0.39$
483 [IQR 0.07, 1.83]), which did not differ significantly from those in the ACPR group
484 ($p_{\text{adj}}=0.271$, rank-sum; Fig 4) or in Day 0 samples with a later recurrence, either in unpaired
485 ($p_{\text{adj}}=0.978$) or in Day0/DRec matched pairs analysis ($n=8$; $\Delta R[\text{DRec-Day0}]=-0.1$ [IQR -0.6,
486 0.8], $p=1.000$, signed-rank test; see Fig S4). Expression of *pvmdr1* was higher at DRec ($n=12$;
487 $R=0.70$ [IQR 0.08, 3.09]) as compared to ACPR ($p_{\text{adj}}=0.016$; Fig 4), but not compared to Day
488 0 samples with a later recurrence, either in unpaired ($p_{\text{adj}}=122$) or Day0/DRec matched pairs
489 analysis ($n=10$; $\Delta R=0.2$ [IQR -0.1, 1.3], $p=0.203$; Fig S4).

490

491 **DISCUSSION**

492

493 This study evaluated CQ therapeutic efficacy for uncomplicated *P. vivax* malaria in Gia Lai
494 province, Vietnam. The success rate for *P. vivax* treatment was 100% by Day 28 and 75.4%
495 by Day 42. All recurrences detected by qPCR ($n=18$) occurred after day 33 in the presence
496 CQ levels below MEC (<100 mg/ml) and were associated with longer PCT of primary
497 infection, younger age, and higher transcript levels of *pvcrt* at baseline. Eighty percent of

498 recurrences (8/10) with WGS data were homologous to primary infections using IBD
499 analysis, leading to a homologous recurrence rate at Day 42 of at least 44% (8/18).

500

501 Among previous CQ TES studies conducted in Vietnam that detected early recurrences (*i.e.*
502 <Day 28) (20,21,23), only one confirmed recurrent infections (n=3) with blood CQ
503 concentration above MEC in Quang Nam in 2011 (20). Although the present study was
504 conceived as a continuation of CQR monitoring in Quang Nam province (20), malaria cases
505 rapidly decreased there after 2013, with mostly residual *P. vivax* by 2015, which was
506 insufficient to conduct classical TES designs due to obvious time and logistic constraints
507 (48). The primary endpoints presented in this study suggest CQ remained largely efficacious
508 in Gia Lai province until 2017, with mostly late recurrences detected after Day 28 in the
509 presence of blood CQ concentrations below MEC, similar to findings in the southern
510 province of Binh Phuoc (22).

511

512 Recurrences occurring after Day 28 of follow-up and in the presence of blood CQ
513 concentrations below MEC have generally been classified as relapses (4,49), which is in line
514 with the frequent relapse phenotype of *P. vivax* strains in the study region (*i.e.* mean time-to-
515 relapse of 41 days (3)). Nevertheless, a thorough revision of *P. vivax* relapses in tropical areas
516 also showed that recrudescence infections of low-grade CQR parasites will become patent at
517 the same time as relapsing infections, due to parasite expansion coincident with the fall in
518 drug levels (7). Some of the findings in the present study undoubtedly suggest that low-grade
519 *P. vivax* CQR should not be ruled out.

520 First, recurrences had a significantly longer PCT than ACPR infections. The difference in
521 PCT was independent of parasite densities at Day 0, suggesting that they were not attributable

522 to an incomplete clearance of a higher parasite inoculum (7). The observation that
523 recurrences occurred in younger individuals (*i.e.* less frequently exposed to *P. vivax* infection
524 throughout life [7, 51], hence with weaker immune response to support drug-mediated
525 clearance) could also have further contributed to the persistence of low-grade CQR parasites.
526 Regardless, given that the median age in both treatment outcome groups falls within early
527 adulthood (18 vs 25 years old) the effect of age, if any, would probably be small.
528 Second, genetic analysis revealed a remarkably high proportion of homologous recurrences
529 using both common microsatellite genotyping (80% rate using 4 MS marker) but also fine-
530 scale genomic approaches, which resulted in a minimum of 44% (8/18) homologous
531 recurrence rate with a degree of relatedness to Day 0 infections above 98% IBD. An earlier
532 review of *P. vivax* clinical studies concluded that relapses in endemic areas commonly occur
533 with heterologous genotypes (as over-repeated liver inoculations lead to the accumulation
534 of genetically diverse hypnozoites), whereas homologous relapses are more likely to occur
535 either in patients recently treated with PQ (*i.e.* those that cleared pre-existing hypnozoites)
536 or in those living in areas with very little parasite genetic diversity (7). More recently, a study
537 conducted in Cambodia investigated recurrent *P. vivax* infections among 20 patients
538 reallocated to an area with no malaria transmission, in order to exclude the possibility of
539 acquiring new infections(10). Although recurrences were comparable to our study in terms
540 of recurrence time (>Day 33) and blood CQ concentrations (<MEC), they were classified as
541 genetically heterologous based on allelic differences by WGS or high-throughput SNP
542 genotyping (6/8), in contrast to the low heterologous rate in our study despite using an IBD
543 approach (2/10). The authors concluded that all recurrences were thus caused by relapses
544 (10). The possibility that IBD-homologous recurrences we identified in Vietnam were also
545 caused by relapses (or even reinfections) with an identical parasite genotype cannot be totally

546 excluded, as we could be underestimating the presence of new alleles due to a lower WGS
547 coverage in our study. However, the latter seems unlikely given: i) the excess of genetically
548 identical parasites in recurrent samples observed using IBD (low genome coverage would
549 underestimate relatedness by IBD compared to IBS analysis, which can misclassify unrelated
550 parasites as homologous due to sharing of alleles by chance); ii) the fact that the number of
551 genetically different sample pairs remained when only the dominant clones were considered
552 in the Cambodian study (thus increased depth does not explain the differences in
553 heterologous rate between studies); iii) the higher rate of polyclonally among primary
554 infections with a later recurrence (89% [16/18]; mean COI=3 by MS) as compared to 50%
555 (10/20) in Cambodia (suggesting a higher genetic diversity in Vietnam that would increase
556 the chance of detecting heterologous recurrences if those were caused by a relapse; indeed,
557 the very limited use of PQ as radical cure in Vietnam may further favor high hypnozoite
558 diversity in the country (50)).

559 Finally, the third finding suggesting some degree of CQR is the higher baseline transcript
560 levels of *pvcrt* in recurrent infections compared to patients with ACPR, independently of
561 parasite stage composition (51,52). This suggests that *P. vivax* parasites expressing higher
562 levels of *pvcrt* may have reduced CQ susceptibility. Data on *pvcrt* expression in response to
563 CQ treatment is limited. In line with our results, a previous study in Brazil found increased
564 *pvcrt* (and *pvm-dr1*) levels in *P. vivax* parasites with CQR phenotype both at Day0 and at time
565 of recurrence (17). A recent study in non-human primates infected with a genetic cross of *P.*
566 *vivax* parasites with different CQ responses identified a strong selection of the chromosome
567 1 region that includes *pvcrt*, linked to the CQR phenotype and upregulation of *pvcrt*
568 expression(18), supporting a role of *pvcrt* in the molecular mechanism of CQR. As for
569 *pvm-dr1*, increased expression found at DRec (although not confirmed in the matched pairs

570 analysis) could hypothetically reflect a mechanism of drug resistance or be a consequence of
571 an altered membrane transport after drug exposure, but current knowledge of the
572 physiological function of *pvm-dr1* is still very limited (53). There is a clear need to further
573 investigate the patterns of *pvcrt* and *pvm-dr1* expression in a higher number of ACPR and
574 recurrent samples (both homologous and heterologous) to elucidate their role in CQ
575 susceptibility.

576 Considering a genetically homologous recurrence as a true recrudescence would imply that
577 parasites observed at Day 0 remain in the human host at levels below qPCR detection limit
578 for several weeks while CQ blood concentrations are over MEC. It has been proposed that
579 *P. vivax* parasites seen in the bloodstream represent only a portion of the total parasite
580 biomass, and that a fraction of parasites may hide in the bone marrow (54–56). Several
581 studies strongly support the role of this tissue as a parasite reservoir, both in human and non-
582 human primates (57)(58). An hypothetical scenario could be one in which a sub-populations
583 of parasites with higher *pvcrt* expression persist in bone marrow parenchyma where CQ
584 levels are lower, leading to homologous recurrences as soon as drug concentrations decrease
585 significantly below the MEC threshold, furthermore coinciding with the time hypnozoite
586 stages are reactivated producing relapse (7).

587

588 A limitation of this study was the impossibility to characterize the phenotype of isolates at
589 time of recurrence to provide further evidence of low-grade CQR recrudescence in addition
590 to our findings at the genomic level. Additionally, for the number of samples eligible for *ex*
591 *vivo* assays or genomic analysis were lower than the total number of patients recruited, a
592 common challenge of *P. vivax* field studies (*i.e.* low parasite density infections and poor
593 adaptation to *ex vivo* conditions). Another difficulty is the intrinsic logistical constraints

594 linked to TES in settings where transmission is being drastically reduced, which questions
595 the feasibility of classical *in vivo* studies under these epidemiological conditions. Such
596 limitation could potentially be overcome once a CQR marker is validated and can be
597 implemented into molecular surveillance, similarly to the ongoing surveillance of *P.*
598 *falciparum* artemisinin resistance in Greater Mekong Subregion based on the *pfkelch-13* gene
599 (59).

600

601 In conclusion, despite the full efficacy of *P. vivax* CQ treatment at Day 28, we find clinical
602 (PCT), genomic (high rate of IBD homology) and transcriptional (increased *pvcrt* expression)
603 evidence suggesting recurrences after Day 28 can be attributable to low-grade CQR
604 recrudescence rather than genetically homologous relapses of liver hypnozoites. Emergence
605 of CQR parasites should be closely monitored. The conclusive identification of a molecular
606 marker is of uttermost importance to unequivocally define *P.vivax* CQR, and detect early
607 warning signs of CQR in molecular surveillance studies conducted in endemic areas. The
608 finding that *pvcrt* (and even *pvm-dr1*) may play a role in *in vivo* CQ susceptibility deserves
609 further attention.

610

611 **ACKNOWLEDGEMENTS**

612

613 We sincerely thank all individuals that accepted to enroll in the trial, all staff from Chu
614 R'Cam CHC and local authorities in Krong Pa district. We are especially grateful to Tran
615 Tuyet Mai, Nguyen Thi Thuy Duong and Do Manh Ha for their support to field work; and to

616 Ric Price and Kamala Thriemer (Menzies School of Health Research) for clinical trial
617 protocol guidelines and helpful discussion.

618 The study was funded by Belgium Development Cooperation (DGD) under the Framework
619 Agreement Program between DGD and ITM (FA3-III, 2014-2016, FA4 2017-2021). This
620 publication uses data from the MalariaGEN SpotMalaria Project, coordinated by the
621 MalariaGEN Resource Centre supported by Wellcome (098051, 090770). Both Chloroquine
622 and Primaquine were provided at no cost by Sanofi.

623

624 **AUTHORS CONTRIBUTIONS**

625

626 Conceived and designed the study: ERV, NVH, AE, ARU; performed the experiments: ERV,
627 NVH, JHK, NTS, NTHH, NTHN, PG, ES; analyzed the data: ERV, NVH, JHK; contributed
628 data collection/logistics/materials/analysis tools: NLH, TTM, NTTD, NDL, TTD, NXX, AE;
629 wrote the paper: ERV, JHK, ARU. All authors read and approved the final version of the
630 manuscript. The authors declare they have no conflicts of interest.

631

632 **REFERENCES**

633

- 634 1. World Health Organization. World Malaria Report 2020. 2020. Available from:
635 [https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020)
636 2020
- 637 2. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the
638 Era of the Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560–70.
- 639 3. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global

- 640 epidemiology of *Plasmodium vivax*. *Am J Trop Med Hyg.* 2016;95(6 Suppl):15–34.
- 641 4. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of
642 chloroquine-resistant *Plasmodium vivax*: A systematic review and meta-analysis.
643 *Lancet Infect Dis.* 2014;14(10):982–91.
- 644 5. World Health Organization. Methods for surveillance of antimalarial drug efficacy.
645 2009. Available from:
646 <https://www.who.int/malaria/publications/atoz/9789241597531/en/>
- 647 6. Baird JK. Chloroquine resistance in *Plasmodium vivax*. *Antimicrob Agents*
648 *Chemother.* 2004;48(11):4075–83.
- 649 7. White NJ. Determinants of relapse periodicity in *Plasmodium vivax* malaria. *Malar J.*
650 2011;10(297).
- 651 8. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation
652 of drug-resistant *Plasmodium vivax*. *Trends Parasitol.* 2012; 28(11):522–9.
- 653 9. Popovici J, Pierce-Friedrich L, Kim S, Bin S, Run V, Lek D, et al. Recrudescence,
654 Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine
655 Efficacy for *Plasmodium vivax* Malaria. *J Infect Dis.* 2019;219(2):315–22.
- 656 10. Popovici J, Friedrich LR, Kim S, Bin S, Run V, Lek D, et al. Genomic analyses reveal
657 the common occurrence and complexity of *plasmodium vivax* relapses in cambodia.
658 *MBio.* 2018 1;9(1).
- 659 11. Noulin F, Borlon C, Van Den Abbeele J, D’Alessandro U, Erhart A. 1912-2012: A
660 century of research on *Plasmodium vivax* in vitro culture. *Trends Parasitol.*
661 2013;29(6):286–94.
- 662 12. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, et al.
663 Identification of the *Plasmodium vivax* mdr- Like Gene (*pvm-dr1*) and Analysis of

- 664 Single-Nucleotide Polymorphisms among Isolates from Different Areas of
665 Endemicity . J Infect Dis. 2005;191(2):272–7.
- 666 13. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et
667 al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association
668 with molecular polymorphisms. PLoS One. 2007;2(10):e1089.
- 669 14. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, et al.
670 Amplification of pvmdr1 Associated with Multidrug-Resistant Plasmodium vivax. J
671 Infect Dis. 2008;198(10):1558–64.
- 672 15. Silva SR, Almeida ACG, Da Silva GAV, Ramasawmy R, Lopes SCP, Siqueira AM,
673 et al. Chloroquine resistance is associated to multi-copy pvcrt-o gene in Plasmodium
674 vivax malaria in the Brazilian Amazon. Malar J. 2018;17(1).
- 675 16. Barnadas C, Ratsimbaoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, et al.
676 Plasmodium vivax resistance to chloroquine in Madagascar: Clinical efficacy and
677 polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother.
678 2008;52(12):4233–40.
- 679 17. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhães BML, Alencar ACC, et
680 al. Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine
681 resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon.
682 PLoS One. 2014;9(8).
- 683 18. Sá JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, et al.
684 Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic
685 cross. Nat Commun. 2019;10(1):4300.
- 686 19. Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The
687 decline of malaria in Vietnam, 1991–2014. Malar J. 2018;17(1):226.

- 688 20. Thanh PV, Van Hong N, Van Van N, Louisa M, Baird K, Xa NX, et al. Confirmed
689 Plasmodium vivax resistance to chloroquine in central Vietnam. Antimicrob Agents
690 Chemother. 2015;59(12):7411–9.
- 691 21. Phan GT, De Vries PJ, Tran BQ, Le HQ, Nguyen N V., Nguyen T V., et al. Artemisinin
692 or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int
693 Heal. 2002;7(10):858–64.
- 694 22. Thuan PD, Ca NTN, Van Toi P, Nhien NTT, Thanh NV, Anh ND, et al. A randomized
695 comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of
696 plasmodium vivax infection in Vietnam. Am J Trop Med Hyg. 2016;94(4):879–85.
- 697 23. Phong NC, Chavchich M, Quang HH, San NN, Birrell GW, Chuang I, et al.
698 Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to
699 chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
700 Malar J. 2019;18(1):10.
- 701 24. National Malaria Control and Elimination Program (NMECP) in Vietnam. Malaria
702 Report 2014 [Internal Report]. NIMPE; 2015.
- 703 25. Rovira-Vallbona E, Hong N Van, Kattenberg JH, Huan RM, Hien NTT, Ngoc NTH,
704 et al. Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the
705 treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam. J
706 Antimicrob Chemother. 2020;75(8).
- 707 26. Ministry of Health Vietnam. Guidelines of diagnosis, treatment and prevention of
708 malaria disease. 2016. Available from: [https://thuvienphapluat.vn/van-ban/The-thao-
709 Y-te/Quy-et-dinh-4845-QD-BYT-Huong-dan-chan-doan-dieu-tri-benh-Sot-ret-2016-
710 321533.aspx](https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quy-et-dinh-4845-QD-BYT-Huong-dan-chan-doan-dieu-tri-benh-Sot-ret-2016-321533.aspx)
- 711 27. Rosanas-Urgell A, Mueller D, Betuela I, Barnadas C, Iga J, Zimmerman PA, et al.

- 712 Comparison of diagnostic methods for the detection and quantification of the four
713 sympatric Plasmodium species in field samples from Papua New Guinea. *Malar J.*
714 2010;9:361.
- 715 28. Wampfler R, Mwingira F, Javati S, Robinson L, Betuela I, Siba P, et al. Strategies for
716 detection of Plasmodium species gametocytes. *PLoS One.* 2013;8(9):e76316.
- 717 29. Basco LK. Field application of in vitro assays sensitivity of human malaria parasites
718 antimalarial drugs. World Health Organization. World Health Organization; 2007.
719 Available from: <https://www.who.int/malaria/publications/atoz/9789241595155/en/>
- 720 30. WWARN In vitro Module. Preparation of predosed plates. WWARN Procedures.
721 2011. Available from:
722 https://www.wwarn.org/sites/default/files/INV03_PreparationOfPredosedPlates.pdf
- 723 31. Woodrow CJ, Dahlström S, Cooksey R, Flegg JA, Le Nagard H, Mentré F, et al. High-
724 Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide
725 Antimalarial Resistance Network (WWARN) In Vitro Analysis and Reporting Tool.
726 *Antimicrob Agents Chemother.* 2013;57(7):3121–30.
- 727 32. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, et al. Evaluation of
728 Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. *J*
729 *Infect Dis.* 2009;199(7):1074–80.
- 730 33. Hong N Van, Delgado-Ratto C, Thanh PV, Van den Eede P, Guetens P, Binh NTH, et
731 al. Population Genetics of Plasmodium vivax in Four Rural Communities in Central
732 Vietnam. *PLoS Negl Trop Dis.* 2016;10(2).
- 733 34. Van den Eede P, Erhart A, Van der Auwera G, Van Overmeir C, Thang ND, Hung
734 LX, et al. High complexity of Plasmodium vivax infections in symptomatic patients
735 from a rural community in central Vietnam detected by microsatellite genotyping. *Am*

- 736 J Trop Med Hyg. 2010;82(2):223–7.
- 737 35. Baniecki ML, Faust AL, Schaffner SF, Park DJ, Galinsky K, Daniels RF, et al.
738 Development of a Single Nucleotide Polymorphism Barcode to Genotype
739 Plasmodium vivax Infections. PLoS Negl Trop Dis. 2015;9(3).
- 740 36. Cowell AN, Loy DE, Sundararaman SA, Valdivia H, Fisch K, Lescano AG, et al.
741 Selective whole-genome amplification is a robust method that enables scalable whole-
742 genome sequencing of Plasmodium vivax from unprocessed clinical samples. MBio.
743 2017;8(1).
- 744 37. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina
745 sequence data. Bioinformatics. 2014;30(15):2114–20.
- 746 38. Pearson RD, Amato R, Auburn S, Miotto O, Almagro-Garcia J, Amaratunga C, et al.
747 Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nat
748 Genet. 2016;48(8):959–64.
- 749 39. Auburn S, Campino S, Miotto O, Djimde AA, Zongo I, Manske M, et al.
750 Characterization of Within-Host Plasmodium falciparum Diversity Using Next-
751 Generation Sequence Data. Snounou G, editor. PLoS One. 2012;7(2):e32891.
- 752 40. Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, et al.
753 Genomic Analysis of Plasmodium vivax in Southern Ethiopia Reveals Selective
754 Pressures in Multiple Parasite Mechanisms. J Infect Dis. 2019;220(11):1738–49.
- 755 41. Henden L. isoRelate. 2016; Available from: <https://doi.org/10.5281/zenodo.197857#>
- 756 42. Martinelli A, Hunt P, Fawcett R, Cravo PVL, Walliker D, Carter R. An AFLP-based
757 genetic linkage map of Plasmodium chabaudi chabaudi. Malar J. 2005;4(1):11.
- 758 43. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-
759 PCR. Nucleic Acids Res. 2001; 29(9):e45.

- 760 44. Golassa L, Kamugisha E, Ishengoma DS, Baraka V, Shayo A, Baliraine FN, et al.
761 Identification of large variation in *pfprt*, *pfmdr-1* and *pfubp-1* markers in *Plasmodium*
762 *falciparum* isolates from Ethiopia and Tanzania. *Malar J.* 2015;14(1):1–9.
- 763 45. Lin JT, Patel JC, Kharabora O, Sattabongkot J, Muth S, Ubalee R, et al. *Plasmodium*
764 *vivax* isolates from Cambodia and Thailand show high genetic complexity and distinct
765 patterns of *P. vivax* multidrug resistance gene 1 (*pvm-dr1*) polymorphisms. *Am J Trop*
766 *Med Hyg.* 2013;88(6):1116–23.
- 767 46. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of
768 parasite clearance in *falciparum* malaria: the parasite clearance estimator. *Malar J.*
769 2011;10:339.
- 770 47. Pava Z, Handayuni I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of
771 *Plasmodium vivax crt-o* Is Related to Parasite Stage but. *Antimicrob Agents*
772 *Chemother.* 2016;60(1):361–7.
- 773 48. Kattenberg JH, Erhart A, Truong MH, Rovira-Vallbona E, Vu KAD, Nguyen THN, et
774 al. Characterization of *Plasmodium falciparum* and *Plasmodium vivax* recent exposure
775 in an area of significantly decreased transmission intensity in Central Vietnam. *Malar*
776 *J.* 2018;17(1).
- 777 49. Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al.
778 Resolving the cause of recurrent *Plasmodium vivax* malaria probabilistically. *Nat*
779 *Commun.* 2019;10(1).
- 780 50. Tinh TT, Mai DTT, Thieu NQ. Quality of malaria diagnosis and treatment in some
781 hospitals in malaria endemic areas (2015-2016). *J Malar Parasite Dis Control*
782 [Vietnam]. 2017;2(98):3–9.
- 783 51. Pava Z, Handayuni I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of

- 784 Plasmodium vivax crt-o is related to parasite stage but not Ex Vivo chloroquine
785 susceptibility. Antimicrob Agents Chemother. 2016;60(1):361–7.
- 786 52. Kim A, Popovici J, Menard D, Serre D. Plasmodium vivax transcriptomes reveal
787 stage-specific chloroquine response and differential regulation of male and female
788 gametocytes. Nat Commun. 2019;10(1).
- 789 53. Dean P, Major P, Nakjang S, Hirt RP, Martin Embley T. Transport proteins of parasitic
790 protists and their role in nutrient salvage. Vol. 5, Front Plant Sci. 2014; 5:153.
- 791 54. Markus MB. Biological concepts in recurrent Plasmodium vivax malaria.
792 Parasitology. 2018; 145(13):1765-1771.
- 793 55. Mayor A, Alano P. Bone marrow reticulocytes: A Plasmodium vivax affair?. Blood.
794 2015; 25(8):1203-5.
- 795 56. Silva-Filho JL, Lacerda MVG, Recker M, Wassmer SC, Marti M, Costa FTM.
796 Plasmodium vivax in Hematopoietic Niches: Hidden and Dangerous. Trends Parasitol.
797 2020;36(5):447–58.
- 798 57. Baro B, Deroost K, Raiol T, Brito M, Almeida ACG, de Menezes-Neto A, et al.
799 Plasmodium vivax gametocytes in the bone marrow of an acute malaria patient and
800 changes in the erythroid miRNA profile. PLoS Negl Trop Dis. 2017;11(4).
- 801 58. Obaldia N, Meibalan E, Sa JM, Ma S, Clark MA, Mejia P, et al. Bone marrow is a
802 major parasite reservoir in plasmodium vivax infection. MBio. 2018;9(3).
- 803 59. Noviyanti R, Miotto O, Barry A, Marfurt J, Siegel S, Thuy-Nhien N, et al.
804 Implementing parasite genotyping into national surveillance frameworks: Feedback
805 from control programmes and researchers in the Asia-Pacific region. Malar J.
806 2020;19(1):271.

TABLES

Table 1. Patients characteristics at baseline.

Variable	N=67
Age group:	
years, median (IQR)	22 (18, 26)
>1-15 years, n (%)	6 (9.0)
>15-25 years, n (%)	37 (55.2)
>25 years, n (%)	24 (35.8)
Sex, males (%)	61 (91.0)
Ethnic group, n (%)	
J'Rai	52 (77.6)
Kinh	15 (22.4)
Weight (kg), median (IQR)	52.5 (48, 61)
Had malaria in the previous year, n (%)	42 (62.7)
Took antimalarials in the previous 14 days	0 (0)
G6PD deficiency	1/67 (1.5)
Fever at enrolment ($\geq 37.5^{\circ}\text{C}$), n (%)	56 (83.6)
Body temperature:	
All ($^{\circ}\text{C}$), median (IQR)	38.5 (37.5, 39.5)
Febrile only ($^{\circ}\text{C}$), median (IQR)	39.0 (38.4, 39.5)
Clinical symptoms:	
Headache, n (%)	67 (100.0)
Fatigue, n (%)	66 (98.5)
Dizziness, n (%)	48 (71.6)
Chills, n (%)	37 (55.2)
Sweats, n (%)	21 (31.3)
Nausea, n (%)	17 (25.4)
Pain, n (%)	6 (9.0)
Vomiting, n (%)	6 (9.0)
Diarrhea, n (%)	3 (4.5)
Hemoglobin (g/dL), median (IQR)	13.5 (12.5, 14.8)
Anemia (Hb <11g/dL), n (%)	7 (10.4)
Parasitological data by LM:	
Asexual parasites/ μl , geomean (95% CI)	5992 (4594, 7815)
Ring-stage %, median (IQR)*	75 (43, 91)
Gametocyte prevalence, n (%)	58 (86.6)
Gametocytes/ μl , geomean (95% CI)	223 (171, 290)

*N=64.

Hb, hemoglobin; G6PD, glucose-6-phosphate dehydrogenase.

Table 2. Study endpoints.

Endpoints	n/N (%) or median (IQR)
Primary:	
ACPR	
Day 28	66/66 (100.0)
Day 42	49/65 (75.4)
Treatment failures (Day 42):	
LCF	3/65 (4.6)
LPF	13/65 (20.0)
Time to recurrence in days	42 (35, 42)
Secondary:	
PCT, hours (n=66)	48.3 (36.8, 60.1)
PC _{1/2} , hours (n=63)	4.1 (3.5, 5.4)
Patients with asexual parasitemia at:	
Day 1	56/67 (83.6)
Day 2	25/67 (37.3)
Day 3	2/66 (3.0)
Patients with gametocytes at:	
Day 1	29/67 (43.3)
Day 2	8/67 (11.9)
Day 3	0/66 (0)
Severe anemia (Hb<7g/dL; day 7)	0/34 (0)

ACPR, Adequate clinical and parasitological response; LCF, late clinical failure; LPF, late parasitological failure; PCT, parasite clearance time; PC_{1/2}, parasite clearance half-life, *i.e.* time to decrease initial parasitemia by half in log-linear phase; Hb, hemoglobin.

Table 3. Genotyping and categorization of recurrent infections. An extended version is provided in Supplemental Materials as Table S4.

Patient code	Microsatellites		SNP barcode		Whole-genome sequencing			
	Discordant MS	Type	Discordant SNP	Type	IBS		IBD	
					Discordant SNP	Type	% IBD	Type
003	0/3	homologous	1/38	heterologous	-	-	-	-
007	0/4	homologous	2/38	heterologous	14.3%	heterologous	35.2%	heterologous
008	0/4	homologous	0/37	homologous	2.2%	homologous	99.9%	homologous
010	-	-	1/38	heterologous	-	-	-	-
018	0/2	homologous	-	-	-	-	-	-
021	4/4	heterologous	-	-	-	-	-	-
022	0/4	homologous	0/37	homologous	6.8%	heterologous	98.1%	homologous
027	0/4	homologous	-	-	2.3%	homologous	99.5%	homologous
028	-	-	-	-	-	-	-	-
034	¼	heterologous	0/38	homologous	1.6%	homologous	99.8%	homologous
037	-	-	-	-	2.0%	homologous	99.7%	homologous
043	0/3	homologous	1/38	heterologous	12.6%	heterologous	99.8%	homologous
044	0/3	homologous	-	-	-	-	-	-
047	1/3	heterologous	0/22	homologous	8.0%	heterologous	32.5%	heterologous
048	0/3	homologous	0/20	homologous	1.7%	homologous	99.5%	homologous
050	0/3	homologous	-	-	-	-	-	-
053	0/4	homologous	0/38	homologous	-	-	-	-
054	0/4	homologous	5/38	heterologous	2.4%	homologous	100%	homologous
Homologous rate:	12/15 (80%)		6/11 (55%)		6/10 (60%)		8/10 (80%)	

MS, microsatellites (Pvmsp1F3+MS4+MS10+PvSal1814); IBS, identity-by-state; IBD, identity-by-descent.

Table 4. Main parasitological and drug-resistance characteristics of *P. vivax* infections, by treatment outcome at baseline.

	ACPR		All recurrences			IBD-homologous recurrences		
	N	median (IQR) or n (%)	N	median (IQR) or n (%)	P-value	N	median (IQR) or n (%)	P-value
Age	49	25 (20, 28)	18	18 (16, 21)	0.002	8	19 (18, 26)	0.103
CQ dose uptake, mg/kg	47	24.5 (24.0, 25.0)	18	24.6 (24.0, 25.5)	0.787	8	24.1 (23.0, 25.2)	0.545
Parasitological indicators:								
Parasitemia at Day 0 (LM), parasites/ μ l*	49	5731.8 (4210.8, 7802.2)	16	6762.3 (3811.7, 11997.0)	0.621	8	12415 (5792, 14031)	0.142
PCT, hours	48	47.5 (36.2, 59.8)	18	54.2 (48.4, 62.0)	0.035	8	60.3 (48.6, 73.0)	0.019
PC _{1/2} , hours	46	4.0 (3.4, 5.2)	17	4.8 (4.0, 5.5)	0.078	8	4.8 (4.2, 5.7)	0.125
Positive at Day 2:								
LM	49	16 (32.7)	18	9 (50)	0.193	8	5 (62.5)	0.13
qPCR	46	19 (41.3)	17	9 (52.3)	0.409	8	5 (62.5)	0.443
Positive at Day 3:								
LM	49	2 (4.0)	17	0 (0)	1.000	8	0 (0)	1.000
qPCR	48	7 (14.6)	17	2 (11.8)	1.000	8	1 (12.5)	1.000
Ex vivo drug sensitivity (Day 0):								
CQ IC50, nM *	13	41.5 (24.4-80.4)	8	38.7 (10.4-108.0)	0.856	5	51.3 (24.3-108.2)	0.301
Candidate molecular markers of CQR (Day 0):								
<i>pvm</i> <i>dr1</i> SNP:								
Y976F	47	34 (72.3)	16	10 (62.5)	0.459	6	3 (50.0)	0.351
F1076L	47	45 (96)	16	15 (93.8)	1.000	6	6 (100)	1.000
<i>pvcrt</i> expression, R	33	0.09 (0.05, 0.22)	16	0.20 (0.15, 0.56)	0.002	8	0.17 (0.14, 0.38)	0.038
<i>pvm</i> <i>dr1</i> expression, R	35	0.11 (0.04, 0.28)	16	0.17 (0.06, 0.47)	0.138	8	0.09 (0.05, 0.35)	0.779

*geometric mean (95% CI).

p-values correspond to results of Wilcoxon rank-sum test (for continuous variables) and Chi-square test (for proportions).

ACPR, adequate clinical and parasitological response; LM, light microscopy; CQR, chloroquine resistance; R, relative expression ratio.




Fig 1. Flow chart of patient screening, enrolment, and follow-up. *LTFU*, loss to follow-up.




Fig 2. Time to parasite clearance. Kaplan-Meier survival curves for total parasite clearance (A) and gametocyte clearance (B). Results are stratified by light microscopy (n=67, blue line) and qPCR (A; n=63, red line) or RTqPCR (B; n=59, red line), respectively. Colored areas indicate 95% confidence intervals. P-values were calculated using log-rank test. One patient with no Day 7 sample by qPCR/RTqPCR was excluded from this analysis.




Fig 3. *Ex vivo* susceptibility to chloroquine in schizont maturation assays (SMA). Graph shows results of CQ-IC50 (nM) in Day 0 samples, stratified by treatment outcome. The type of recurrence based on identity-by-descent (IBD) analysis is indicated with colored dots (black, IBD-homologous recurrence; grey, IBD-heterologous recurrence; white, undetermined by WGS). *ACPR*, *adequate clinical and parasitological response*.




Fig 4. Gene expression of *pvcr1* and *pvmdr1*. Expression ratio R of *pvcr1* (A) or *pvmdr1* (B) relative to reference gene *β -tubulin* is displayed in log-scale. Samples are stratified by treatment outcome and day of collection. Horizontal lines indicate median and IQR. The type of recurrence based on identity-by-descent (IBD) analysis is indicated with colored dots (black, IBD-homologous recurrence; grey, IBD-heterologous recurrence; white, undetermined by WGS). Adjusted p-values from pairwise Wilcoxon rank-sum test with Benjamini-Hochberg correction for multiple testing are reported. ACPR, *adequate clinical and parasitological response*.

Supplemental Material

807

Table S1. PCR reaction mixes and thermocycling conditions.

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.22.21250265>; this version posted February 2, 2021. The copyright holder for this preprint

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

A) PCR reaction mixes and thermocycling conditions for microsatellite genotyping.

Gene	Primer sequences	qPCR mix (µl)	Thermocycling conditions
<i>pvmSP1F3</i>	msp1F3-fwdp: 5'-GGAGAACATAAGCTACCTGTCC-3'	Hotstart 10x Buffer 2 dNTP mix (20mM) 2 MgCl2 (25 mM) 1.6 Forward Primer (10µM) 0.5 Reverse Primer (10µM) 0.5 Hotstart Taq Polymerase (Qiagen) 0.2 H ₂ O Molecular Biology grade 8.2 DNA 5	1x 95°C, 10min 95°C, 15sec 25x 59°C, 30sec 72°C, 30sec 1x 72°C, 10min
	msp1F3-revp: 5'-GTTGTACTTGGTCTTCTCCC-3'		
	msp1F3-fwdn: VIC-5'-CAAGCCTACCAAGAATTGATCCCCAA-3'	Hotstart 10x Buffer 2 dNTP mix (20mM) 2 MgCl2 (25 mM) 1.6 Forward Primer (10µM) 0.5 Reverse Primer (10µM) 0.5 Hotstart Taq Polymerase (Qiagen) 0.2 H ₂ O Molecular Biology grade 8.2 Primary PCR product 5	1x 95°C, 10min 95°C, 15sec 25x 59°C, 30sec 72°C, 30sec 1x 72°C, 10min
	msp1F3-revn: 5'-ATTACTTTGTCTAGTCTCGGCGTAGTCC-3' + tail		
MS4	MS4-fwd: PET-5'- CGATTTACTGTTGACGCTGAA-3'	Hotstart 10x Buffer 2.5 dNTP mix (20mM) 0.5 Forward Primer (10µM) 2 Reverse Primer (10µM) 2 Acetylated BSA (0,1µg/µl) 0.25 Hotstart Taq Polymerase (Qiagen) 0.2 H ₂ O Molecular Biology grade 12.55 DNA 5	1x 95°C, 10min 95°C, 30sec 40x 60°C, 40sec 72°C, 40sec 1x 72°C, 10min
	MS4-rev: 5'-CTGTCTTCAAAGGAACATGCTCGATGA-3'		
MS10	MS10fwd: FAM-5'-TTATCCCTGCTGGATGTGAA-3'	Hotstart 10x Buffer 2.5 dNTP mix (20mM) 0.5 Forward Primer (10µM) 2 Reverse Primer (10µM) 2 Acetylated BSA (0,1µg/µl) 0.25 Hotstart Taq Polymerase (Qiagen) 0.2 H ₂ O Molecular Biology grade 12.55 DNA 5	1x 95°C, 10min 95°C, 30sec 40x 58°C, 40sec 72°C, 40sec 1x 72°C, 10min
	MS10rev: 5'-CTGTCTTTCCTCAGGTGGGACTTGTT-3'		
PvSal1814	PvSal1814-fwd: FAM-5'-AAACAGGCATTAGGTTTAAGAGTG-3'	Hotstart 10x Buffer 5 dNTP mix (20mM) 0.5 Forward Primer (10µM) 1 Reverse Primer (10µM) 1 acetylated BSA (0,1µg/µl) 0 Hotstart Taq Polymerase (Qiagen) 0.2 H ₂ O Molecular Biology grade 32.3 DNA 10	1x 95°C, 5min 95°C, 30sec 40x 54°C, 40sec 72°C, 40sec 1x 72°C, 8min
	PvSal1814-rev: CAGTGGCTTCTTCTTAGTGG		

B) PCR reaction mixes and thermocycling conditions for *pvm₁* genotyping

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.22.21250265>; this version posted February 2, 2021. The copyright holder for this preprint

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

Gene	Primer sequences	qPCR mix (μl)	Thermocycling conditions
<i>pvm₁</i>	GoIPvmdr-1 OF 5'-CGCCATTATAGCCCTGAGCA-3' GoIPvmdr-1 OR 5'-TCTCACGTCGATGAGGGACT-3'	5X Buffer 10 MgCl ₂ (25 mM) 5 dNTP mix (20mM) 0.5 Forward Primer (10μM) 1 Reverse Primer (10μM) 1 GoTaq Polymerase (Promega) 0.25 H ₂ O Molecular Biology grade 27.25 DNA 5	1x 95°C, 5min 95°C, 15sec 33x 55°C, 30sec 72°C, 1min 1x 72°C, 7min
	Lin-mdr1_Fw 5'-ATAGTCATGCCCCAGGATTG-3' Lin-mdr1_Rev 5'-CCTTTTGAAGGACAGCTTTG-3'	Buffer 10 MgCl ₂ (25 mM) 5 dNTP mix (20mM) 0.5 Forward Primer (10μM) 1 Reverse Primer (10μM) 1 GoTaq Polymerase (Promega) 0.25 H ₂ O Molecular Biology grade 31.25 Primary Product 1	1x 95°C, 5min 95°C, 15sec 33x 55°C, 30sec 72°C, 1min 1x 72°C, 7min

Data S1 (Excel [S1_Data_GRC.xlsx]). Genetic Report Card (SpotMalaria). The dataset contains drug-resistance genotypes as well as the SNP barcode (Sheet A). An explanatory table with detail of sequenced positions and reference/mutant codon is provided in Sheet B.

Table S2. Whole-genome sequencing coverage.
 medRxiv preprint doi: <https://doi.org/10.1101/2021.01.22.21250265>; this version posted February 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

Patient code	Day 0			Day of recurrence		
	parasites/ μ l	coverage (mean X \pm SD)	% missing positions	parasites/ μ l	coverage (mean X \pm SD)	% missing positions
007	41506	41.2 \pm 52	0.8%	769	21.4 \pm 33	4.4%
008	6068	27.6 \pm 51	13.8%	3428	45.0 \pm 43	0.4%
010	5431	6.8 \pm 11	0.9%	212	1.6 \pm 15	88.7%
018	2408	25.5 \pm 37	2.9%	103	3.3 \pm 22	81.9%
022	13430	38.9 \pm 54	1.6%	444	44.0 \pm 46	0.4%
027	5517	37.1 \pm 57	4.6%	3268	42.2 \pm 42	0.4%
034	4010	42.1 \pm 56	2.1%	1536	45.5 \pm 47	0.4%
037	11401	38.5 \pm 55	2.5%	310	37.5 \pm 41	0.6%
043	55892	42.7 \pm 39	0.3%	7477	34.2 \pm 40	0.8%
044	274	46.4 \pm 51	0.6%	68	2.5 \pm 9	48.6%
047	4927	25.0 \pm 55	27.8%	91	35.0 \pm 39	0.6%
048	13965	50.1 \pm 47	0.3%	856	16.9 \pm 41	35.5%
053	11262	8.6 \pm 40	81.0%	2469	21.8 \pm 52	34.4%
054	14096	32.3 \pm 50	4.0%	440	35.7 \pm 55	3.9%
All		33.1 \pm 47	10.2%		27.6 \pm 38	21.5%

808




Fig S1. Distribution of discordant SNPs by whole-genome sequencing. The proportion of discordant SNPs was determined by calculating the Prevosti distance between all pair-wise comparisons (*i.e.* number of allelic differences/number of possible differences) using the R-package *poppr* (<https://cran.r-project.org/web/packages/poppr/index.html>). Due to the high likelihood of multiclonal infections in *P. vivax*, distances were fitted as the sum of four Gaussian distributions using the R-package *mixtools* (<https://cran.r-project.org/web/packages/mixtools/index.html>). The distribution with the lowest proportion of discordant SNPs (red line) was used to define the threshold (mean plus 3x the standard deviation for that distribution) of homologous recurrence for identify-by-state (IBS) analysis.




Fig S2. qPCR standard curves for *pvcr1*, *pvmdr1* and β -*tubulin*. Standard curves were prepared using 10-fold serial dilutions of dsDNA fragments covering the targeted region in each gene of interest (range 4000000-4 copies/ μ l). Amplification efficiencies calculated from cycle threshold (Ct) versus dsDNA copy number (log transformed) plots were 1.88, 1.90 and 1.84 for *pvcr1*, *pvmdr1* and β -*tubulin*, respectively.

Table S3. Microsatellites genotyping. Results of allele calling using Genetools software. Shared alleles between

sample pairs at Day 0 and Day of recurrence (DRc) are indicated in bold. medRxiv preprint doi: <https://doi.org/10.1101/2021.01.22.21250265>; this version posted February 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

Patient code	Day	PvMSP1.F3					MS4		MS10		PvSal1814					
		Allele1	Allele2	Allele3	Allele4	Allele5	Allele1	Allele2	Allele1	Allele2	Allele1	Allele2	Allele3	Allele4	Allele5	Allele6
003	Day0	264	313				195	198	216		528	543	558			
	DRc	264						198			528	543				
007	Day0	229		264	278	313	198	201	201	207	599	614	629			
	DRc		259			313		201	201		599	614	629			
008	Day0	276					195		201		563	578				
	DRc	276	325				195		201		563	578				
010	Day0	259	306				204		213							
	DRc															
018	Day0	259	264	316			198	201	204	213	510	525	540			
	DRc	259							204							
021	Day0	253		300				204	195					573	588	603
	DRc		259				201			207	528	543	558			
022	Day0	219	278	327			198		195		599	614	629			
	DRc		278				198		195		599					
027	Day0			325	374		201		198		555	584	599			
	DRc	147	197		374		201		198		555	584	599			
028	Day0	147	197	325	374		201		198							
	DRc															
034	Day0	325					201		198			581		596		
	DRc	325					201		198		555		584			
037	Day0	259					201		201							
	DRc															
043	Day0	264	272						204		555	569	584			
	DRc		272				198		204				584	614		
044	Day0	264					204		210		584	599	614			
	DRc	264							210		584	599	614			
047	Day0	253	264				195	201	207		599					
	DRc	253	264					201	204							
048	Day0	264					223		201							
	DRc	264					223		201		599					
050	Day0	264					198		213		620	635				
	DRc	264							213		620					
053	Day0	258					201		201			573	588			
	DRc	258					201		201		558	573	588	603		
054	Day0	250					213		204		620	635				
	DRc	250					213		204		620	635				

Table S4. Genotyping and categorization of recurrent infections.

Patient code	Parasite density by LM (p/µl)		Microsatellites				SNP barcode				Whole-genome sequencing					
			COI		Discordant MS	Type	COI		Disc. SNP	Type	COI		IBS		IBD	
	Day0	DRec	Day0	DRec			Day0	DRec			Day0	DRec	Disc. SNP	Type	% IBD	Type
003	3470	0	3	2	0/3	homologous	1	1	1/38	heterologous	-	-	-	-	-	-
007	41506	769	4	3	0/4	homologous	2	1	2/38	heterologous	>1	>1	14.3%	heterologous	35.2%	heterologous
008	6068	3428	2	2	0/4	homologous	1	1	0/37	homologous	1	1	2.2%	homologous	99.9%	homologous
010	5431	212	2	-	-	-	1	2	1/38	heterologous	-	-	-	-	-	-
018	2408	103	3	1	0/2	homologous	2	-	-	-	>1	-	-	-	-	-
021	3369	1225	3	3	4/4	heterologous	2	-	-	-	-	-	-	-	-	-
022	13430	444	3	1	0/4	homologous	1	2	0/37	homologous	1	>1	6.8%	heterologous	98.1%	homologous
027	5517	3268	3	3	0/4	homologous	1	-	-	-	1	1	2.3%	homologous	99.5%	homologous
028	6849	24	4	-	-	-	1	-	-	-	-	-	-	-	-	-
034	4010	1536	2	2	1/4	heterologous	1	2	0/38	homologous	1	1	1.6%	homologous	99.8%	homologous
037	11401	310	1	-	-	-	1	-	-	-	1	1	2.0%	homologous	99.7%	homologous
043	55892	7477	3	2	0/3	homologous	1	2	1/38	heterologous	>1	1	12.6%	heterologous	99.8%	homologous
044	274	68	3	3	0/3	homologous	-	2	-	-	>1	-	-	-	-	-
047	4927	91	2	2	1/3	heterologous	2	2	0/22	homologous	>1	>1	8.0%	heterologous	32.5%	heterologous
048	13965	856	1	1	0/3	homologous	1	2	0/20	homologous	1	1	1.7%	homologous	99.5%	homologous
050	5852	0	2	1	0/3	homologous	1	-	-	-	-	-	-	-	-	-
053	11262	2469	2	4	0/4	homologous	1	2	0/38	homologous	-	1	-	-	-	-
054	14096	440	2	2	0/4	homologous	1	2	5/38	heterologous	1	1	2.4%	homologous	100%	homologous
Homologous recurrence rate:			12/15 (80%)				6/11 (55%)				6/10 (60%)				8/10 (80%)	

LM, light microscopy; DRec, samples at day of recurrence; COI, complexity of infection; MS, microsatellites (Pvmsp1F3+MS4+MS10+PvSal1814); IBS, identity-by-state; IBD, identity-by-descent.




Fig S3. Gene expression of *pvcr1* and *pvmdr1* and proportion of ring-stages in infections at Day 0. Gene expression ratios (R) of *pvcr1* (A) and *pvmdr1* (B) relative to reference gene β -*tubulin* are displayed in log-scale (y axis). Linear regression was fitted to data (black line with standard error bounds in grey) did not show an association between R and ring-stage percentage (*pvcr1*: coef.=-0.0003, p=0.886; *pvmdr1*: coef.=-0.001, p=0.655).




Fig S4. Gene expression of *pvcr1* and *pvmdr1* in Day 0/DRec paired samples. Differences in gene expression ratio R between infections at DRec and paired infections at Day 0 are shown for both *pvcr1* (A) and *pvmdr1* (B). Type of recurrences based on identity-by-descent (IBD) analysis is shown with coloured bars (black, IBD-homologous recurrence; grey, IBD-heterologous recurrence; white, undetermined by WGS).